BACKGROUND: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. METHODS: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. CONCLUSION: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.
BACKGROUND: Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data. METHODS: We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy. CONCLUSION: In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Hassan K Dakik; Daniel J Moskovic; Peter J Carlson; Eric P Tamm; Wei Qiao; Robert A Wolff; James L Abbruzzese; David R Fogelman Journal: Cancer Chemother Pharmacol Date: 2011-08-18 Impact factor: 3.333
Authors: Robert L Fine; David R Fogelman; Stephen M Schreibman; Manisha Desai; William Sherman; James Strauss; Susan Guba; Riolan Andrade; John Chabot Journal: Cancer Chemother Pharmacol Date: 2007-04-18 Impact factor: 3.333
Authors: Ana De Jesus-Acosta; George R Oliver; Amanda Blackford; Katharine Kinsman; Edna I Flores; Lalan S Wilfong; Lei Zheng; Ross C Donehower; David Cosgrove; Daniel Laheru; Dung T Le; Ki Chung; Luis A Diaz Journal: Cancer Chemother Pharmacol Date: 2011-07-29 Impact factor: 3.333